SCHEMBL3609627

SCHEMBL3609627

CC(=O)Oc1ccc(-c2nc(NC(=N)N)sc2C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
PKM P14618 3/20 0.51
ALOX5 P09917 1/20 0.50
MAPT P10636 4/20 0.47
MAPK1 P28482 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HTT P42858 2/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 3/20 0.47
XIAP P98170 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 4/20 0.46
GAA P10253 1/20 0.46
GSTO1 P78417 1/20 0.45
PLTP P55058 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600153 0.87 ALDH1A1 (0.48) ALDH1A1PKMALOX5MAPTMAPK1
SCHEMBL3601806 0.86 ALOX5 (0.49) ALDH1A1PKMALOX5MAPTMAPK1
SCHEMBL3606192 0.80 PLTP (0.56) ALDH1A1PKMALOX5MAPTMAPK1
SCHEMBL3597492 0.79 DHODH (0.54) ALDH1A1PKMALOX5MAPTMAPK1
SCHEMBL3604783 0.79 ALDH1A1 (0.48) ALDH1A1PKMALOX5MAPTMAPK1
SCHEMBL3598191 0.79 ALOX5 (0.63) ALDH1A1PKMALOX5MAPTMAPK1
SCHEMBL3601789 0.77 KDM4E (0.60) ALDH1A1PKMMAPTMAPK1KDM4E
SCHEMBL3601552 0.74 ATP4A (0.61) ALDH1A1PKMALOX5MAPTMAPK1
SCHEMBL727518 0.74 ALDH1A1 (0.41) ALDH1A1PKMPOLBHSD17B10CYP1A2
SCHEMBL3613064 0.74 ALDH1A1 (0.47) ALDH1A1MAPTKDM4EPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 ALDH1A1 1302/4885PKM 1420/4885ALOX5 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.